Aristocort (triamcinolone acetonide) is a mid-potency topical corticosteroid formulated for the targeted treatment of inflammatory dermatoses. It functions by modulating inflammatory pathways, reducing erythema, pruritus, and edema associated with various skin conditions. This product is indicated under medical supervision for both acute flare management and maintenance therapy in chronic dermatological disorders. Its efficacy is supported by extensive clinical use and pharmacological validation.

Features

• Active ingredient: Triamcinolone acetonide (0.025%, 0.1%, or 0.5% concentrations)
• Formulations: Cream, ointment, lotion
• Vehicle options: Optimized for different skin types and lesion characteristics (occlusive ointment for dry/scaly conditions; non-greasy cream for intertriginous areas)
• Preservative-free options available for sensitive skin
• pH-balanced to minimize irritation
• Rapid cutaneous absorption with low systemic bioavailability

Benefits

• Provides rapid anti-inflammatory and antipruritic action, often within 24–48 hours of application
• Reduces lichenification, scaling, and erythema through vasoconstrictive and immunosuppressive mechanisms
• Minimizes risk of skin atrophy compared to higher-potency steroids when used appropriately
• Supports barrier repair in eczematous dermatoses by controlling underlying inflammation
• Available in multiple strengths and vehicles for tailored therapeutic approaches
• Cost-effective relative to newer branded alternatives with comparable efficacy profiles

Common use

Aristocort is commonly prescribed for corticosteroid-responsive dermatoses including atopic dermatitis, contact dermatitis, nummular eczema, psoriasis (excluding widespread plaque psoriasis), lichen planus, and seborrheic dermatitis. It may also be used off-label for discoid lupus erythematosus, granuloma annulare, and certain forms of vitiligo (under specialist supervision). The product is not indicated for rosacea, perioral dermatitis, or untreated cutaneous infections.

Dosage and direction

Apply a thin film to affected areas 2–4 times daily, depending on severity and physician recommendation. Use the lowest effective dose and frequency to achieve control. For occlusive dressing technique (limited to severe, resistant lesions): apply sparingly, cover with airtight dressing, and monitor for 12-hour intervals. Duration should generally not exceed 2 weeks continuously without reevaluation. Pediatric and facial application should be limited to 1 week unless specifically directed. Wash hands after application unless treating hands.

Precautions

Avoid use near eyes, mucous membranes, or broken skin. Do not apply under diapers or tight clothing unless advised (increased systemic absorption risk). Discontinue if irritation develops. Not for ophthalmic, intravaginal, or intraoral use. Use with caution in patients with liver impairment, diabetes, or tuberculosis. Prolonged use may cause skin atrophy, telangiectasia, or hypopigmentation. Monitor for signs of HPA axis suppression with large surface area/long-term use.

Contraindications

Hypersensitivity to triamcinolone acetonide or any component of the formulation. Contraindicated in viral skin infections (herpes simplex, varicella), fungal infections, untreated bacterial infections, and parasitic infestations. Not recommended during pregnancy unless potential benefit justifies potential risk (Category C). Avoid in patients with circulatory compromise or skin ulcers.

Possible side effect

Common: transient burning/stinging, dryness, folliculitis, itching.
Infrequent: skin atrophy, striae, hypertrichosis, acneiform eruptions, hypopigmentation.
Rare: allergic contact dermatitis, secondary infection, miliaria, telangiectasia.
Systemic effects (with excessive use): HPA axis suppression, hyperglycemia, glaucoma (if periocular application), Cushing’s syndrome.

Drug interaction

No well-documented pharmacokinetic interactions. Potential for increased systemic absorption when used with other topical corticosteroids. Occlusive dressings may enhance penetration and systemic effects. Concurrent use with other immunosuppressants may increase infection risk.

Missed dose

Apply as soon as remembered unless close to next scheduled dose. Do not double apply. Maintain regular application schedule; inconsistent use may reduce efficacy.

Overdose

Topical overdose may cause systemic corticosteroid effects including hypercortisolism, adrenal suppression, and hyperglycemia. Treatment involves discontinuation and supportive care. Acute topical overdose requires cleansing of affected area. In case of ingestion, seek immediate medical attention—gastric lavage may be indicated if consumed within 1 hour.

Storage

Store at 20–25°C (68–77°F). Keep tube tightly closed. Protect from freezing, excessive heat, and direct sunlight. Do not store in bathroom or damp areas. Keep out of reach of children and pets. Discard any product showing separation, discoloration, or unusual odor.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Diagnosis and treatment should be determined by a qualified healthcare provider. Use strictly as prescribed. Individual results may vary. Full prescribing information available upon request.

Reviews

“Consistently effective for moderate eczema flares without the atrophy risk of higher-potency steroids. Vehicle options allow customization for different body regions.” — Dermatologist, 12 years experience
“Preferred mid-potency steroid for maintenance therapy in chronic hand dermatitis. Patients report good tolerability and rapid itch relief.” — Clinical Pharmacist
“Reliable and cost-effective. Have used in practice for decades with predictable results when used appropriately.” — General Practitioner
“Not suitable for severe psoriasis but excellent for lichen simplex chronicus and nummular eczema.” — Dermatology Nurse Practitioner
“Some patients experience initial stinging, but this typically resolves with continued use. Good option for steroid-responsive facial dermatitis (short-term).” — Patient feedback collated through clinic surveys